Updated on: February 5, 2026 / 8:19 PM EST / CBS News
The Trump administration on Thursday launched TrumpRx, a new prescription drug listing site intended to offer lower direct-to-consumer prices. The site lists dozens of medicines at steep discounts from list prices after the administration struck agreements with more than a dozen drugmakers, including major companies such as Pfizer and Novo Nordisk.
TrumpRx does not sell drugs directly. Instead, it provides a printable, gold-embossed coupon users can present at pharmacies. Examples on the site include Wegovy injection pens listed at $199 for the first two months and $349 thereafter, far below the list price of $1,349.02, and a unit of Gonal-F (used in IVF) listed at $252 — an 83% discount from the sticker price. Novo Nordisk has offered similar Wegovy discounts through its NovoCare Pharmacy program.
At a White House event unveiling the site, President Trump called TrumpRx “one of the most transformative health care initiatives of all time.” Joe Gebbia, an Airbnb founder serving as the administration’s Chief Design Officer, said more drugs will be added over time.
How much TrumpRx will change what most Americans pay is uncertain. Most people obtain medications through insurance, so the direct-to-patient discounts may not alter insured patients’ costs; the site itself advises consumers with insurance to check their copay first. Sean Sullivan, a health economist at the University of Washington, told CBS News last year that the direct-to-patient approach is largely “a sideshow and branding opportunity,” noting most patients have drug coverage and few will buy medications with cash unless a drug is not covered, such as some weight-loss or erectile-dysfunction treatments.
Still, steep cash discounts could matter for the uninsured, people with high deductibles, and patients whose drugs aren’t covered — including some users of weight-loss and IVF medications. Centers for Medicare and Medicaid Services administrator Dr. Mehmet Oz urged consumers to check whether medications are available at the site’s discounted prices.
Beyond TrumpRx, the administration has pressed drugmakers to lower prices and reached deals to offer certain drugs to Medicaid patients at most-favored-nation prices, tying U.S. prices to those paid in other high-income countries. Lawmakers and presidents from both parties have long criticized the comparatively high prices Americans pay for medications.
Drugmakers routinely raise list prices at the start of each year. Data from drug pricing research nonprofit 46brooklyn showed manufacturers raised list prices for 947 brand-name drugs this January and lowered prices on 20, with a median list-price increase of 4% so far in 2026. In some cases, however, list prices have fallen substantially — Eliquis fell 43% and Jardiance fell 44% after being among the first 10 drugs selected for Medicare price negotiations under the Inflation Reduction Act.
The Consumer Price Index for prescription drugs, which tracks transaction costs rather than list prices, rose 2% between December 2024 and December 2025, and has declined by less than 1% since President Trump’s second-term inauguration in January 2025.
Dr. Céline Gounder contributed to this report.